TSO3 Inc

TSO3 — Investor Presentation (November 2018)

20 slides from TSO3's investor presentation, November 2018

  1. Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing

    To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation | November 2018 1

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certain risks

  3. Slide 3: Vision and Purpose: A Sterile Device for Every Patient

    VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Patient 3

  4. Slide 4: One Disruptive Technology – Two Large Markets

    One Disruptive Technology – Two Large Markets Established Base Business Emerging Opportunity Operating Room & Central Sterile Gastrointestinal Supply Department Process/ U.S. ~10,000 Hospitals & Ambulatory Technology ~15M colonoscopies performed Surgery Centers1 annually5 Canada ~1,400 Hospitals2 >5

  5. Slide 5: Breakthrough Technologies: 138 Patents + 49 Patents Pending Worldwide

    Breakthrough Technologies /// 138 Patents + 49 Patents Pending Worldwide 1. Insert Room Temperature Instruments Into a Warm Chamber 2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time 3. Micro Condensation Forms on the Instruments Condensation Layer Dual Sterilants T

  6. Slide 6: Proven Value Proposition

    Proven Value Proposition* New Metric: Cost per Instrument Sterilized, not Cost per Cycle Competition STERIZONE® VP4 Sterilizer Saves up to 50% in Operating Costs 2 STERIZONE® VP4 Sterilizers = 3+ of the Competition in Throughput The Least Expensive Option In the Market Today * Actual customer result

  7. Slide 7: Disruptive Technology for OR Support

    Disruptive Technology for OR Support The STERIZONE® VP4 Sterilizer is a dual sterilant, low-temperature sterilization system that uses vaporized hydrogen peroxide (H2O2) and ozone. Features Advantages Benefits • Dual Chemistry • Simple Single Cycle • Lowest Cost per Instrument Operation Sterilized •

  8. Slide 8: Proven Value Proposition – Independent of Customer Size

    Proven Value Proposition – Independent of Customer Size Fewer Cycles Fewer Sterilizers Better Efficiency “STERIZONE® VP4 50% less cost per “We had 4 [competitor] Sterilizers, now STERIZONE® VP4 Sterilizer is 3 times instrument sterilized than we have 2 STERIZONE® VP4 Sterilizers.” more efficient tha

  9. Slide 9: Value of a Customer

    Value of a Customer Potential Revenue Per US Customer* (Assuming 2 units, 10 Yr Product Life) “Razor” Capital Equipment Sales $200k-$300k 1-4 units per facility Approx. $0.9m-$1.2m Higher-Margin Revenue Proprietary Consumables $20k-$30k/Sterilizer/Year Opportunity per Customer* “Razorblades” Service

  10. Slide 10: Commercialization Approach - CSSD

    Commercialization Approach - CSSD LEVERAGE EARLY INCREASE MARKET ESTABLISH STRONG SUPPORT WITH DIRECT ADOPTERS AWARENESS CUSTOMER SALES, CLINICAL AND TARGETING METRICS TECHNICAL PERSONNEL • 59 sterilizers installed in • >5,000 targeted customers • High Use Facilities • Trained in-house personnel US

  11. Slide 11: Sales and Marketing Activities

    Sales and Marketing Activities • Sell Direct to End Users • Consultative Sales Approach • Sell With Partners/Agents • System Wide Sales • Strategic Pricing – Lower Capital ASPs in exchange for speed • New Approaches • Cost of Ownership Tools • Digital Ads • Trade Shows TSX:TOS 11

  12. Slide 12: Commercial Activity: As of November 6, 2018

    Commercial Activity: As of November 6, 2018 ~5,000 accounts targets in N. America 59 Units Installed in US and Canada >200 opportunities 90 Units Installed or Committed in NA quoted 8 Sales Reps in 8 Territories – going to 11 +10 Units Committed in October 2018 Alone 200 unit goal for 2019 TSX:TOS 1

  13. Slide 13: Endoscopy Sterilization – A Greenfield Opportunity

    Endoscopy Sterilization – A Greenfield Opportunity Established Base Business Emerging Opportunity Operating Room & Central Sterile Process/ Gastrointestinal Supply Department U.S. ~10,000 Hospitals & Ambulatory Technology ~15M colonoscopies performed Surgery Centers1 annually5 Canada ~1,400 Hospital

  14. Slide 14: How Shifts Happen: Market Change

    How Shifts Happen Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation • Cost Reduction = Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 14

  15. Slide 15: Modernizing GI Endoscope Reprocessing

    Modernizing GI Endoscope Reprocessing Decades old processes with only incremental improvement “Despite reprocessing in accordance with US guidelines, viable Old microbes and biologic debris persisted in clinically used [GI] endoscopes, suggesting current reprocessing guidelines are not sufficient to

  16. Slide 16: TSO3 Obtains Expanded Endoscope Clearances

    TSO3 Obtains Expanded Endoscope Clearances May 9, 2018 - TSO3 received FDA 510(k) clearance for the terminal sterilization of multi-channeled flexible endoscopes using the Company’s STERIZONE® VP4 Sterilizer • Hospitals can terminally sterilize gastrointestinal endoscopes within the cleared intended

  17. Slide 17: Recent Customer Activity

    Recent Customer Activity Altru Health System Improves Patient Care with Expanded Use of Cutting-Edge Sterilization Technology June 15, 2018 - “Being the inaugural facility to offer terminal sterilization of endoscopes using the TSO3 technology, provides our patients with a level of safety above curr

  18. Slide 18: Summary

    Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Razor/Razorblade Business Model SUMMARY First- First-to- to-Market FDA- FDA-cleared Device for Terminal Sterilization of Colonoscopes, Duodenoscopes and Gastroscopes Direct Commercialization Strategy Financially Sound TSX:TOS 18

  19. Slide 19: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise Stock Price (11/23/18) CAD$0.48 52 Week High-Low CAD$2.83-$0.38 Shares Outstanding (mrq) (no warrants) 93.2M Average Daily Volume (90 day) 122,900 Market Capitalization CAD$44.8M Institutional Holdings ~15% Total Revenue (mrq) $0.8M

  20. Slide 20: T Sh,

    T Sh,

TSO3 — Investor Presentation (November 2018) on 6ix